Dr. Raymond U. Osarogiagbon
Claim this profileBaptist Memorial Hospital and Cancer Center-Memphis
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
27 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage II
Stage I
2Non-Small Cell Lung Cancer
Stage IV
PD-L1 positive
PD-L1 negative
Affiliated Hospitals
Clinical Trials Raymond U. Osarogiagbon is currently running
Sotorasib
for Non-Small Cell Lung Cancer
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Recruiting2 awards Phase 219 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
More about Raymond U. Osarogiagbon
Clinical Trial Related5 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Raymond U. Osarogiagbon has experience with
- Docetaxel
- Gemcitabine
- Pemetrexed Disodium
- Atezolizumab
- Cisplatin
- Carboplatin
Breakdown of trials Raymond U. Osarogiagbon has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Tumors
Gastrointestinal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Raymond U. Osarogiagbon specialize in?
Raymond U. Osarogiagbon focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage II.
Is Raymond U. Osarogiagbon currently recruiting for clinical trials?
Yes, Raymond U. Osarogiagbon is currently recruiting for 2 clinical trials in Memphis Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Raymond U. Osarogiagbon has studied deeply?
Yes, Raymond U. Osarogiagbon has studied treatments such as Docetaxel, Gemcitabine, Pemetrexed Disodium.
What is the best way to schedule an appointment with Raymond U. Osarogiagbon?
Apply for one of the trials that Raymond U. Osarogiagbon is conducting.
What is the office address of Raymond U. Osarogiagbon?
The office of Raymond U. Osarogiagbon is located at: Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee 38120 United States. This is the address for their practice at the Baptist Memorial Hospital and Cancer Center-Memphis.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.